BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing

Reuters

2025/10/14

BioCryst Pharmaceuticals to Acquire Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Expanding HAE Portfolio and Securing Strategic Financing

BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from Blackstone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545075-en) on October 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575291113"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575291113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575291113?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575291113","market":"nz","top_or_hot":-1,"title":"BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioCryst Pharmaceuticals to Acquire Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Expanding HAE Portfolio and Securing Strategic Financing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from <a href=\"https://laohu8.com/S/BX\">Blackstone</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545075-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-14 19:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioCryst Pharmaceuticals to Acquire Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Expanding HAE Portfolio and Securing Strategic Financing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from <a href=\"https://laohu8.com/S/BX\">Blackstone</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545075-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BBT3K403.USD","symbol_name":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL9Tq55y:1","article_id":"2575291113","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575291113","pubTimestamp":1760439746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from Blackstone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4585":"ETF&股票定投概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4547":"WSB热门概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4135":"资产管理与托管银行","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ATXS":"Astria Therapeutics Inc","BX":"黑石","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","NDAQ":"纳斯达克OMX交易所","BCRX":"BioCryst制药"},"translate_title":"BioCryst Pharmaceuticals将收购Astria Therapeutics，扩大HAE产品组合并获得战略融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATXS":0.9,"BX":0.9,"NDAQ":0.9,"BCRX":0.9},"content_text":"BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing\n    \n\n        BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics in a deal valued at approximately $700 million, with Astria shareholders receiving a mix of cash and stock representing an implied value of $13.00 per share. The transaction, unanimously approved by both companies' boards, is expected to close in the first quarter of 2026, subject to customary closing conditions. Following the completion of the deal, Jill C. Milne, Ph.D., CEO of Astria, will join the BioCryst board of directors. BioCryst anticipates immediate operating synergies and expects the acquisition to be accretive to operating profit in the first full year after the anticipated launch of navenibart. The cash portion of the consideration will be funded with cash on hand and a strategic financing facility from Blackstone.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545075-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}